Sector News

BioLineRx buys Agalimmune to expand cancer pipeline

March 23, 2017
Life sciences

BioLineRx has bought Agalimmune to expand its immuno-oncology pipeline. The takeover adds the synthetic alpha-gal immunotherapy AGI-134 to BioLineRx’s pipeline as the drug nears the start of a first-in-human trial in solid tumors.

Tel Aviv, Israel-based BioLineRx is paying $6 million (€5.6 million) upfront—split evenly between cash and stock—to buy Agalimmune. In return for the outlay, BioLineRx is gaining AGI-134, a preclinical-stage asset it thinks could make immunotherapies effective against solid tumors that evade the attacks of today’s therapeutics.

“AGI-134 harnesses naturally occurring, pre-existing antibodies to elicit a tumor-specific immune response that is unique to the treated individual and provides a universal, small-molecule approach to personalized immunotherapy,” BioLineRx CEO Philip Serlin said in a statement. “The subsequent stimulation and recruitment of T cells, which recognize the patient’s own neo-antigens, to the tumor site, has the potential of transforming ‘cold’ tumors into ‘hot’ ones.”

London-based Agalimmune, which has labs in Sandwich, U.K., and Boston, Massachusetts, has generated limited data to support Serlin’s belief in AGI-134. Agalimmune has tested the candidate in a preclinical model of melanoma and run combination studies with a PD-1 checkpoint inhibitor that BioLineRx sees as suggesting it can broaden the use of such therapeutics while boosting the rate and duration of the responses they trigger.

BioLineRx will now take responsibility for putting AGI-134 through more rigorous tests. The drug is set to enter a phase 1 trial in solid tumor patients in the first half of next year. By injecting the drug into tumors, BioLineRx thinks it can trigger a process that starts with the binding of antigal antibodies and proceeds to activate complement-dependent and antibody-dependent cellular cytotoxicity.

The candidate grew out of work Uri Galili, Ph.D., performed on the use of intratumoral alpha-gal glycolipids to treat solid tumors at the University of Massachusetts. Other companies, such as Horizon Discovery’s Avvinity Therapeutics, are also trying to use abundant antigal antibodies to treat cancer.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach